In conclusion, M-18C was able to reduce the release of TNF-α and IL-1β by inhibiting the expression of NLRP3 and ASC proteins, repairing the intestinal barrier, and regulating the intestinal flora and serum metabolism, thereby alleviating LPS-induced AKI. Here, TNF is linked to acute kidney injury.